<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141058">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01674283</url>
  </required_header>
  <id_info>
    <org_study_id>OVO-12-08</org_study_id>
    <nct_id>NCT01674283</nct_id>
  </id_info>
  <brief_title>Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization</brief_title>
  <official_title>Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OVO R &amp; D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OVO R &amp; D</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The success of in vitro fertilization is based mainly on uterine implantation embryo. An
      excessive uterine contractility may interfere with implantation by a movement of the embryo
      in the uterus. The inhibition of the uterine contractility may have a positive effect on
      success rate of in vitro fertilization. It is through parenteral injection of glucagon and
      its spasmolytic effect on various smooth muscles and thereby on the uterine muscle, at the
      time of embryo transfer, the investigators intend to improve the pregnancy rates obtained
      after IVF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women will have a cycle of in vitro fertilization (IVF) and follow the standard protocol
      established by the clinic ovo or the fertility clinic of CHUM. On the day of embryo
      transfer, the investigators will administer 1 mg of Glucagon or placebo intramuscularly 10
      minutes before the embryo transfer. The uterine contractility will be measured by ultrasound
      before and after injection to document the impact of Glucagon on it and we will proceed to
      embryo transfer.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Uterine muscle relaxation</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine if the intramuscular administration of 1mg of Glucagon 10 minutes before the embryo transfer is associated with a uterine muscle relaxation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Embryo implantation and pregnancy rate</measure>
    <time_frame>7 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine if the intramuscular administration of 1mg of Glucagon 10 minutes before the embryo transfer is associated with higher implantation and pregnancy rates than during embryo transfer without glucagon.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Women With Fertility Disorder</condition>
  <arm_group>
    <arm_group_label>Glucagon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of Glucagon.
The second recording is doing the same way 10 minutes after the Glucagon injection, just before the embryo transfer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium chloride 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of the placebo.
The second recording is doing the same way 10 minutes after the placebo injection, just before the embryo transfer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <arm_group_label>Glucagon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Sodium chloride 0.9%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women doing fertility treatment at the clinic ovo or fertility clinic of CHUM

          -  Less than 40 years old

          -  Women with stimulate in vitro fertilization cycle

          -  Women able to give her consent

        Exclusion Criteria:

          -  Body mass index &gt; 35 kg/m2

          -  Women with diabetes

          -  Women with hypertensive disorders

          -  Women with a blood pressure greater or equal to 140/90 mmHg at the randomization
             visit

          -  Cons-indication to taking Glucagon:

               -  Hypersensitivity to product

               -  Pheochromocytoma or history of pheochromocytoma

               -  Insulinoma

               -  Taking a beta-blocker (drug interactions)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Himaya, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>clinique ovo and CHUM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kécelle Viaud, RN</last_name>
    <phone>(514) 798-2000</phone>
    <phone_ext>759</phone_ext>
    <email>k.viaud@cliniqueovo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie Leblanc, RN</last_name>
    <phone>514-798-2000</phone>
    <phone_ext>617</phone_ext>
    <email>s.leblanc@cliniqueovo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Ovo</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4P 2S4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shirley Brugerie, Director</last_name>
    </contact>
    <contact_backup>
      <last_name>Kécelle Viaud, RN</last_name>
      <phone>514-798-2000</phone>
      <phone_ext>759</phone_ext>
      <email>s.leblanc@cliniqueovo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Himaya Eric, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 21, 2013</lastchanged_date>
  <firstreceived_date>August 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
